Real-world treatment outcome of advanced Chinese NSCLC EGFR exon 20 insertion patients.

被引：1
|
作者：
Wang, Yan
Yang, Guangjian
Li, Jun
Xu, Haiyan
Yang, Lu
Xu, Fei
Yang, Yaning
Xia, Bing
Zhu, Viola Weijia
Qiu, Weini
Ou, Sai-Hong Ignatius
机构：
[1] Chinese Acad Med Sci, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Dept Med Oncol, Natl Clin Res Ctr Canc, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Ctr Clin Lab Med, Beijing, Peoples R China
[5] Chinese Acad Med Sci, Natl Clin Res Ctr Canc, Dept Comprehens Oncol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[6] USC Norris Cance Ctr, Los Angeles, CA USA
[7] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Sch Med, Orange, CA 92668 USA
[8] Healthy, Beijing, Peoples R China
[9] Univ Calif, Chao Family Comprehens Canc Ctr, Orange, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9043
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
    Mok, T. S. K.
    Liu, G.
    Nyaw, S. F.
    Curcio, H.
    Cortot, A.
    Kam, T. Y.
    Descourt, R.
    Chik, Y. K.
    Cheema, P. K.
    Gwinnutt, J. M.
    Churchill, E. N.
    Nyborn, J.
    Curran, E.
    Yin, Y.
    Chong, K.
    Tanaka-Chambers, Y.
    Kretz, J.
    Cadranel, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1698 - S1699
  • [42] Real-World treatment outcomes for advanced NSCLC in Greece
    Kokkotou, Eleni
    Stournara, Lamprini
    Mani, Maria
    Gkiozos, Ioannis
    Tsagouli, Sofia
    Syrigos, Nikolaos
    Burke, Thomas
    Desiniotis, Andreas
    Dimitriadis, Ioannis
    Charpidou, Andriani
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [43] Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having EGFR Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer -American Society of Clinical Oncology CancerLinQ Study
    Behera, Madhusmita
    Jiang, Renjian
    Huang, Zhonglu
    Bunn, Becky
    Wynes, Murry W.
    Switchenko, Jeffrey
    V. Scagliotti, Giorgio
    Belani, Chandra P.
    Ramalingam, Suresh S.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (06):
  • [44] EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting
    Subramanian, J.
    Gregg, J.
    Berktas, M.
    Jiang, Z.
    Li, J.
    Taylor, A.
    Leighl, N.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S438 - S439
  • [45] A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
    Chouaid, Christos
    Filleron, Thomas
    Debieuvre, Didier
    Perol, Maurice
    Girard, Nicolas
    Dansin, Eric
    Lena, Herve
    Gervais, Radj
    Cousin, Sophie
    Otto, Josiane
    Schott, Roland
    Planchard, David
    Madroszyk, Anne
    Kaderbhai, Coureche
    Dubray-Longeras, Pascale
    Hiret, Sandrine
    Pichon, Eric
    Clement-Duchene, Christelle
    Chenuc, Gaelle
    Simon, Gaetane
    Bosquet, Lise
    QUantin, Xavier
    TARGETED ONCOLOGY, 2021, 16 (06) : 801 - 811
  • [46] A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
    Christos Chouaid
    Thomas Filleron
    Didier Debieuvre
    Maurice Pérol
    Nicolas Girard
    Eric Dansin
    Hervé Lena
    Radj Gervais
    Sophie Cousin
    Josiane Otto
    Roland Schott
    David Planchard
    Anne Madroszyk
    Courèche Kaderbhai
    Pascale DUBRAY-Longeras
    Sandrine Hiret
    Eric Pichon
    Christelle Clément-Duchêne
    Gaëlle Chenuc
    Gaëtane Simon
    Lise Bosquet
    Xavier QUantin
    Targeted Oncology, 2021, 16 : 801 - 811
  • [47] Co-occurring genomic alterations and treatment outcomes in patients with EGFR exon 20 insertion positive NSCLC
    Montenegro, G. Bravo
    Vanderwalde, A.
    Raez, L.
    Nieva, J.
    Feldman, R.
    Herrmann, A.
    Nagasaka, M.
    Ikpeazu, C.
    Mamdani, H.
    Pai, S.
    Wozniak, A.
    Spira, A.
    Lopes, G.
    Liu, S.
    Kim, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S605 - S606
  • [48] Short-term efficacy of furmonertinib in treatment of NSCLC patients with EGFR exon20 insertion.
    Zhou, Xiaoyue
    Dong, Huajie
    Li, Peng
    Wu, Changling
    Lu, Hongjun
    Xiao, Mingzhe
    Zhou, Tong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling
    Zwierenga, F.
    Zhang, L.
    Melcr, J.
    Schuuring, E.
    van Veggel, B. A. M. H.
    de Langen, A. J.
    Groen, H. J. M.
    Groves, M. R.
    van der Wekken, A. J.
    LUNG CANCER, 2024, 197
  • [50] A real-world study of camrelizumab in the treatment of advanced lung cancer patients.
    Gu, Kangsheng
    Bi, Minghong
    Zhao, Dong
    Cheng, Huaidong
    Wang, Genhe
    Qian, Hong
    Min, Xuhong
    Xia, Xiaoyang
    Wang, Fan
    Hu, Zhiqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345